Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding

被引:178
|
作者
Taggart, CC [1 ]
Cryan, SA
Weldon, S
Gibbons, A
Greene, CM
Kelly, E
Low, TB
O'Neill, SJ
McElvaney, NG
机构
[1] Beaumont Hosp, Dept Med, Pulm Res Div, Educ & Res Ctr, Dublin, Ireland
[2] Royal Coll Surgeons Ireland, Sch Pharm, Dublin 2, Ireland
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2005年 / 202卷 / 12期
关键词
D O I
10.1084/jem.20050768
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Secretory leucoprotease inhibitor ( SLPI) is a nonglycosylated protein produced by epithelial cells. In addition to its antiprotease activity, SLPI has been shown to exhibit anti-inflammatory properties, including down-regulation of tumor necrosis factor alpha expression by lipopolysaccharide (LPS) in macrophages and inhibition of nuclear factor (NF)-kappa B activation in a rat model of acute lung injury. We have previously shown that SLPI can inhibit LPS-induced NF-kappa B activation in monocytic cells by inhibiting degradation of I kappa B alpha without affecting the LPS-induced phosphorylation and ubiquitination of I kappa B alpha. Here, we present evidence to show that upon incubation with peripheral blood monocytes (PBMs) and the U937 monocytic cell line, SLPI enters the cells, becoming rapidly localized to the cytoplasm and nucleus, and affects NF-kappa B activation by binding directly to NF-kappa B binding sites in a site-specific manner. SLPI can also prevent p65 interaction with the NF-kappa B consensus region at concentrations commensurate with the physiological nuclear levels of SLPI and p65. We also demonstrate the presence of SLPI in nuclear fractions of PBMs and alveolar macrophages from individuals with cystic fibrosis and community-acquired pneumonia. Therefore, SLPI inhibition of NF-kappa B activation is mediated, in part, by competitive binding to the NF-kappa B consensus-binding site.
引用
收藏
页码:1659 / 1668
页数:10
相关论文
共 50 条
  • [41] NF-κB p65 activates fibronectin gene expression in hepatocytes
    Lee, BH
    Kim, MS
    Park, RW
    Kim, IS
    MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 176A - 176A
  • [42] Activation of p65 NF-κB protein by p210BCR – ABL in a myeloid cell line (P210BCR – ABL activates p65 NF-κB)
    Malika Hamdane
    Marie-Helene David-Cordonnier
    Jean Claude D'Halluin
    Oncogene, 1997, 15 : 2267 - 2275
  • [43] A novel DNA recognition mode by the NF-κB p65 homodimer
    Chen, YQ
    Ghosh, S
    Ghosh, G
    NATURE STRUCTURAL BIOLOGY, 1998, 5 (01) : 67 - 73
  • [44] NIK and Cot cooperate to trigger NF-κB p65 phosphorylation
    Wittwer, Tobias
    Schmitz, M. Lienhard
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 371 (02) : 294 - 297
  • [45] Preventing the Progression of Osteoarthritis by Inhibiting the NF-κB/p65 Pathway
    Lv, Meng
    Wang, Hua
    Jiang, Wei
    Luo, Qi
    Zhou, Tianjian
    Lin, Bowen
    NANOSCIENCE AND NANOTECHNOLOGY LETTERS, 2017, 9 (12) : 2046 - 2053
  • [46] Regulation of NF-κB activity through lysine monomethylation of p65
    Ea, Chee-Kwee
    Baltimore, David
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (45) : 18972 - 18977
  • [47] Small molecule and nucleic acid modulators of NF-κB p65
    Harki, Daniel
    Widen, John
    Struntz, Nicholas
    Passow, Kellan
    Kempema, Aaron
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [48] Reptin physically interacts with p65 and represses NF-κB activation
    Qiu, Hua
    Gao, Yueqiu
    Mao, Dewen
    FEBS LETTERS, 2015, 589 (15) : 1951 - 1957
  • [49] Post-translational modification of RelA(p65) NF-κ B
    Campbell, KJ
    Perkins, ND
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 1087 - 1089
  • [50] Epidermal p65/NF-κB signalling is essential for skin carcinogenesis
    Kim, Chun
    Pasparakis, Manolis
    EMBO MOLECULAR MEDICINE, 2014, 6 (07) : 970 - 983